GlassScriptPhysician profile
Long T Hoang
NPI 1477516128
$8,755.08
in general payments reported to CMS, 2019-2025
46 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,213 · 2020: $759 · 2021: $1,235 · 2022: $1,396 · 2023: $1,653 · 2024: $1,369 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,007 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,007.18 |
| Education | $144.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,610.19 | 2019-2025 | |
| Janssen Biotech, INC. | $1,565.44 | 2019-2025 | Stelara, Tremfya |
| Boston Scientific Corporation | $888.91 | 2019-2025 | Exalt Model D, Spyglass, Spyglass |
| Takeda Pharmaceuticals U.S.A., INC. | $492.11 | 2020-2025 | Gattex, Eohilia |
| Pfizer INC. | $269.45 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $264.07 | 2019-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $261.61 | 2019-2023 | Ocaliva |
| Celltrion USA INC. | $228.92 | 2024 | Zymfentra, Vegzelma |
| Janssen Scientific Affairs, LLC | $227.82 | 2019-2023 | Stelara, Remicade, Simponi |
| Steris Corporation | $217.01 | 2019-2020 | |
| Madrigal Pharmaceuticals | $174.71 | 2024-2025 | Rezdiffra |
| Sirtex Medical INC | $146.56 | 2025 | Sir-Spheres Microspheres |
| Shionogi INC | $131.65 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $121.19 | 2022 | |
| Celgene Corporation | $120.27 | 2022-2023 | Zeposia |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Long Hoang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.